Type 2 Diabetes Mellitus Clinical Trial
Official title:
Yo Puedo! Diabetes Self-Management Education + mHealth in Mexico City
NCT number | NCT03159299 |
Other study ID # | 1511016854 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 8, 2017 |
Est. completion date | June 30, 2019 |
Verified date | April 2020 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aims of this study are:
1. To translate an evidence-based diabetes self-management education (DSME) program, Yo
Puedo!, to the cultural norms, expertise of providers, and systems of care in Seguro
Popular clinics in Mexico. The program will be adapted through a collaborative team of
diabetes experts in the US and Mexico, Seguro Popular clinic administrators, physicians,
nurses and adults with type 2 diabetes (T2D) in Mexico City, Mexico. This will include
development and testing of a theory-based mHealth (pictorial text-messaging) component.
2. To evaluate the feasibility (process of implementation, fidelity of sessions,
attendance, attrition), acceptability (interviews with nurse, CHW, participants) and
preliminary efficacy of Yo Puedo!+mHealth in adults with T2D in Mexico City. A
randomized, controlled pilot study design will be used in which 40 adults with T2D are
randomized to the Yo Puedo! + mHealth or a wait-list control condition with the
hypothesis that clinical [A1C, body mass index (BMI), blood pressure (BP)], T2D
self-management, and self-efficacy outcomes will be greater in You Puedo!+mHealth
participants compared to the wait-list control condition at 3 and 6 month follow-up. A
secondary hypothesis that the Yo Puedo! + mHealth program is feasible and acceptable to
adults with T2D and providers and that fidelity of the program will be maintained.
Status | Completed |
Enrollment | 47 |
Est. completion date | June 30, 2019 |
Est. primary completion date | April 28, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 65 Years |
Eligibility |
Inclusion Criteria: Phase 1: - For provider interviews/focus groups: administrator or health care provider at Seguro Popular clinic with at least 3 months experience. - For adult interviews/focus groups: 21-65 years of age and have had T2D for at least one year Phase 2: - Age 21-65 years; receiving care for T2D at a Seguro Popular clinic; diagnosed with T2D with A1C >8.0% and duration = 5 years; medically stable and safe to exercise; and have a cell phone (MMS text-messaging will be provided). Exclusion Criteria: Phase 2: - Cognitive impairment, severe untreated clinical depression in the past 6 months, major cardiac event in past 12 months, uncontrolled blood pressure, resting tachycardia, renal failure, severe peripheral neuropathy, treatment of T2D with insulin, and participation in focus groups or interviews. |
Country | Name | City | State |
---|---|---|---|
United States | Yale School of Nursing | Orange | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University | Universidad Iberoamericana |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Satisfaction With Program | This measure will be used to evaluate the acceptability of the Yo Puedo program. Participants will be given a short survey and interview about their experience and satisfaction with the program. | 6 months | |
Other | Rate of Recruitment | Rates of recruitment will be collected by researchers to evaluate feasibility. | through study completion, about 1 year | |
Other | Attrition | This will be collected by researchers to evaluate feasibility. The number of participants who do not complete the study interventions and the reasons why will be recorded by study personnel. | through study completion, about 1 year | |
Other | Protocol Implementation | This will be collected by researchers to evaluate feasibility. The CHWs will complete a Protocol Implementation Form after each session that documents attendance, length of the session, content of session, protocol implementation, and any deviation from protocol implementation | through study completion, about 1 year | |
Other | Fidelity of Yo Puedo Sessions | This will be collected by researchers to evaluate feasibility. A study Co-Investigator will observe 10% of sessions to evaluate fidelity of Yo Puedo sessions. | through study completion, about 1 year | |
Primary | Change in Hemoglobin A1C From Baseline | The change in A1C from baseline to 6 months is the result of the Generalized Linear Mixed Models (GLMM) with an intent-to-treat analysis that was used. HbA1c was measured from finger stick blood sample. | Baseline, 3, 6 months | |
Secondary | Baseline Systolic and Diastolic Blood Pressure | Systolic and diastolic BP will be measured according to practice standards. Two readings separated by 1 minute will be averaged | Baseline | |
Secondary | Change in Baseline Systolic and Diastolic Blood Pressure From Baseline | Systolic and diastolic BP will be measured according to practice standards. Two readings separated by 1 minute will be averaged | 3 months | |
Secondary | Change in Baseline Systolic and Diastolic Blood Pressure From Baseline | Systolic and diastolic BP will be measured according to practice standards. Two readings separated by 1 minute will be averaged | 6 months | |
Secondary | Body Mass Index (BMI) | A calibrated electronic scale will be used to record weight and a wall-based stadiometer will be used to record height. Weight and height will be combined to report BMI in kg/m^2. | Baseline | |
Secondary | Change in Body Mass Index (BMI) From Baseline | A calibrated electronic scale will be used to record weight and a wall-based stadiometer will be used to record height. Weight and height will be combined to report BMI in kg/m^2. | 3 months | |
Secondary | Change in Body Mass Index (BMI) From Baseline | A calibrated electronic scale will be used to record weight and a wall-based stadiometer will be used to record height. Weight and height will be combined to report BMI in kg/m^2. | 6 months | |
Secondary | Diabetes Self-management | Measured by the Summary of Diabetes Self-Care Activities questionnaire, a multi-dimensional12-item scale with items on general diet, specific diet, monitoring blood glucose, foot care, and smoking | Baseline | |
Secondary | Change in Diabetes Self-management From Baseline | Measured by the Summary of Diabetes Self-Care Activities questionnaire, a multi-dimensional12-item scale with items on general diet, specific diet, monitoring blood glucose, foot care, and smoking | 3 months | |
Secondary | Change in Diabetes Self-management From Baseline | Measured by the Summary of Diabetes Self-Care Activities questionnaire, a multi-dimensional12-item scale with items on general diet, specific diet, monitoring blood glucose, foot care, and smoking | 6 months | |
Secondary | Dietary Intake | Dietary intake will be evaluated by a two-day diet history | Baseline | |
Secondary | Change in Dietary Intake From Baseline | Dietary intake will be evaluated by a two-day diet history | 3 months | |
Secondary | Change in Dietary Intake From Baseline | Dietary intake will be evaluated by a two-day diet history | 6 months | |
Secondary | Physical Activity | Physical activity will be measured by accelerometer, using the Actigraph Actigraphy, a 3-axial accelerometer. | Baseline | |
Secondary | Change in Physical Activity From Baseline | Physical activity will be measured by accelerometer, using the Actigraph Actigraphy, a 3-axial accelerometer. | 3 months | |
Secondary | Change in Physical Activity From Baseline | Physical activity will be measured by accelerometer, using the Actigraph Actigraphy, a 3-axial accelerometer. | 6 months | |
Secondary | Diabetes Self-Efficacy | Self-efficacy will be measured by the Stanford Diabetes Self-Efficacy Scale, an 8-item scale specific to T2D self-management self-efficacy. | Baseline | |
Secondary | Change in Diabetes Self-Efficacy From Baseline | Self-efficacy will be measured by the Stanford Diabetes Self-Efficacy Scale, an 8-item scale specific to T2D self-management self-efficacy. | 3 months | |
Secondary | Change in Diabetes Self-Efficacy From Baseline | Self-efficacy will be measured by the Stanford Diabetes Self-Efficacy Scale, an 8-item scale specific to T2D self-management self-efficacy. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |